secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2024-09-17T23:59:59+00:00
Accession:  0001558370-24-012836
Event type: other_material
Sentiment:  positive
Materiality: 0.82
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor signs binding term sheet with Nippon Shinyaku for European deramiocel rights; $15M equity + $20M upfront
--------------------------------------------------------------------------------

- Nippon Shinyaku to commercialize deramiocel in EU, UK and other European countries; Capricor receives double-digit revenue share.
- Up to $715M in milestone payments plus $20M upfront upon definitive agreement (expected Q4 2024); combined milestones now ~$1.5B.
- Private placement of 2.8M shares at $5.36 (20% premium to 60-day VWAP) raises ~$15M; proceeds extend cash runway into 2026.
- Capricor to develop and manufacture deramiocel; meeting with EMA planned to discuss European expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000155837024012836/0001558370-24-012836-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000155837024012836/capr-20240916x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-012836

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer